|

Bleeding In Thrombocytopenia Explained

RECRUITINGSponsored by Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
Actively Recruiting
SponsorSanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
Started2018-12-04
Est. completion2022-10-01
Eligibility
Age18 Years+
View on ClinicalTrials.gov →

NCT03505086

Summary

Multicenter case cohort study investigating clinical risk factors for clinically relevant bleeding in hemato-oncology patients, as well as bleeding related biomarkers during intensive treatment.

Eligibility

Age: 18 Years+
Inclusion Criteria:

Inclusion criteria are mentioned below and differ for part A and B of the study.

* Admission in the hospital. (part A and B)
* Age ≥ 18 years. (part A and B)

AND:

• Hemato-oncology patient, including MDS and AA, admitted for treatment (chemotherapy, SCT) who is (expected to become) thrombocytopenic with platelet counts of \< 50 for expected at least 5 days and who will possibly be treated with one or more prophylactic platelet transfusions. (part A and B)

OR:

• Hemato-oncology patient who had previous intensive chemotherapy or stem cell transplantation and who is admitted to the hematology ward for disease or treatment related events or complications. (part A only)

Exclusion Criteria:

• Patients with myeloproliferative disorders.

Conditions5

BleedingCancerHematologic NeoplasmsHemorrhagePlatelet Transfusion

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.